Gene Correction in Autologous CD34+ Hematopoietic Stem Cells (HbS to HbA) to Treat Severe Sickle Cell Disease

NCT04819841 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

15

Enrollment

INDUSTRY

Sponsor class

Conditions

Sickle Cell Disease

Interventions

GENETIC: nula-cel Drug Product

Sponsor

Kamau Therapeutics